TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04195971

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Liver CT
Description: Liver CT with precontrast, dual arterial phase, portal venous phase, and delayed phase.
Study: NCT00641511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYN117 (nepicastat)
Description: 120 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: once per day placebo capsules
Study: NCT01584544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Study: NCT02371265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence and retention package
Description: Based on formative research findings, the following core components of the B+ study intervention have been designed and will be stepped in at the study sites to improve early retention in care and adherence:~* Workflow modification: 1) Redefinition of key roles of MCH nurses and task shifting to community health workers (CHW's), and 2) enhanced patient tracking via improved management of registries/charts;~* Adherence and retention package: 1) Creation of Adherence Committees at each site to coordinate and systematize patient follow-up, 2) active patient follow-up and home visits by community health workers (CHWs or activistas), 3) use of text messaging to patients by MCH nurses, 4) improved and intensified counseling coordinated with active CHW and text follow-up, and 5) intensified and improved Option B+ training and supportive supervision.
Study: NCT03931239

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Study subjects will be vaccinated with 3 (three) vaccine doses. The first vaccine will be administered intramuscularly starting at 6-12 weeks of age followed by two doses at four-week interval
Description: An openlabel, multicentric, bridging study to assess the safety of Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae type b Conjugate Vaccine (Adsorbed) manufactured by Serum Institute of India Pvt. Ltd in Vietnamese infants aged 6-12 weeks, given as a 3-dose regime, with 4 week intervals between the doses
Study: NCT03563105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Ox-Imager Mini (Desaturation)
Description: Vascular Occlusion Test
Study: NCT03733509

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative Block
Description: One shot adductor canal nerve block with 20ml of bupivacaine 0.25% through surgical incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Block
Description: One shot adductor canal nerve block with 20ml of bupivacaine 0.25% mid-thigh

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative Placebo
Description: One shot adductor canal nerve infusion with 20ml of saline solution through surgical incision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Placebo
Description: One shot adductor canal nerve infusion with 20ml of saline solution mid-thigh
Study: NCT00440557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa 3 times weekly /once weekly
Description: Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)
Study: NCT02542488

Intervention type: OTHER
Intervention: STOPBANG Questionnaire
Description: 8 question screening tool comprised of the following questions:~S: Do you Snore loudly? T: Do you often feel tired during daytime? O: Has anyone observed you stop breathing during your sleep? P: Do you have high blood pressure? B: Is your BMI \>35 kg/m2? A: Are you \>50 years old? N: Is your neck circumference \>40cm? G: Is your gender male?

Intervention type: DIAGNOSTIC_TEST
Intervention: Overnight pulse oximetry
Description: All participants will be given a Masimo Rad8 pulse oximeter to take home and apply to their finger overnight to measure their heart rate and oxygen saturations while they sleep.

Intervention type: OTHER
Intervention: Epworth Sleepiness Scale
Description: A questionnaire that rates how tired they are doing everyday tasks
Study: NCT01584544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1350mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Study: NCT02271165

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulin (Hizentra)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulin (Hizentra)
Study: NCT02999087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of RT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of RT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of RT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avelumab
Description: IV infusion of avelumab (10 mg/kg over 1 hour) once every 2 weeks. Avelumab will start on Day-8 together with cetuximab and subsequently every 2 weeks during the course of RT. Avelumab with be continued every 2 weeks for an additional 12 months following RT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avelumab
Description: IV infusion of avelumab (10 mg/kg over 1 hour) once every 2 weeks. Avelumab will start on Day-8 together with cetuximab and subsequently every 2 weeks during the course of RT. Avelumab with be continued every 2 weeks for an additional 12 months following RT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 100 mg/m² IV after hyperhydration and at a maximal rate of 1 mg/min, on days 1, 22, 43.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: RT will be performed using IMRT (intensity modulated radiotherapy), with a simultaneous integrated boost (SIB) technique. RT dose to the GTV will be 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions). Prophylactic dose will be 52.8 Gy in 1.6 Gy daily fractions over 6.5 weeks (33 fractions).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: RT will be performed using IMRT (intensity modulated radiotherapy), with a simultaneous integrated boost (SIB) technique. RT dose to the GTV will be 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions). Prophylactic dose will be 52.8 Gy in 1.6 Gy daily fractions over 6.5 weeks (33 fractions).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: RT will be performed using IMRT (intensity modulated radiotherapy), with a simultaneous integrated boost (SIB) technique. RT dose to the GTV will be 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions). Prophylactic dose will be 52.8 Gy in 1.6 Gy daily fractions over 6.5 weeks (33 fractions).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: RT will be performed using IMRT (intensity modulated radiotherapy), with a simultaneous integrated boost (SIB) technique. RT dose to the GTV will be 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions). Prophylactic dose will be 52.8 Gy in 1.6 Gy daily fractions over 6.5 weeks (33 fractions).
Study: NCT01714986

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Affect School

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Body Awareness Therapy
Study: NCT01810679

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perceval S Aortic Heart Valve
Description: Perceval S Sutureless Aortic Heart Valve
Study: NCT01711827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: oral
Study: NCT00801866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravitreal administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Panretinal Photocoagulation
Description: Panretinal Photocoagulation
Study: NCT03112239

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light-Emitting Diode Therapy (LEDT)
Description: Light-emitting diode, has effects similar to the photobiomodulation by low-level laser intensity.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light-Emitting Diode Therapy (LEDT)
Description: Light-emitting diode, has effects similar to the photobiomodulation by low-level laser intensity.
Study: NCT01311466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplantation
Study: NCT02975687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR T cells
Description: CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
Study: NCT02429531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23 (Sanofi Pasteur MSD)
Description: Intramuscular injection of Pneumovax 23 vaccine (0.5 ml).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumovax 23 (Sanofi Pasteur MSD)
Description: Intramuscular injection of Pneumovax 23 vaccine (0.5 ml).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhim Vi (Sanofi Pasteur MSD)
Description: Intramuscular injection of Typhim Vi vaccine (0.5 ml).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Typhim Vi (Sanofi Pasteur MSD)
Description: Intramuscular injection of Typhim Vi vaccine (0.5 ml).
Study: NCT01758757

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Study: NCT02883244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft-Picks Advanced
Description: Soft-picks Advanced will be used once a day to clean interdental sites at home.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Floss
Description: Floss will be used once a day to clean interdental sites at home.
Study: NCT02567929

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol group
Description: Patient will be anesthetized by using propofol infusion during operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane group
Description: Patient will be anesthetized by using sevoflurane inhalation during operation.
Study: NCT02328066

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI used by trained endoscopists
Description: Examination of colon lesions, using NBI and NICE classification, by endoscopists who previously performed an easy learning program. The learning program consists on the reading of two reference articles and a tutorial explaining the NICE classification. This tutorial shows several lesions and describes the characteristic features in which the classifications focus on.
Study: NCT01325012

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subgluteal Sciatic Nerve Block
Description: Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle. After catheter placement, outcome measures will be assessed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Popliteal Sciatic Nerve Block
Description: Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.
Study: NCT01736046

Intervention type: RADIATION
Intervention: CT Enterography
Description: Diagnostic CT Enterography Scan (CTE)~Subjects will have their scheduled diagnostic CTE scan done according to St. Paul's Hospital radiology department standard procedures. Subjects will be randomly assigned to undergo a low dose CT Enterography scan either before or after the diagnostic scan. The radiologists who are blinded to the technique used will then interpret the scans to look for signs of Crohn's disease. The low dose scan will be compared to the standard scan in terms of it's ability to detect signs of Crohn's disease.
Study: NCT01012492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
Study: NCT01271621

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation
Description: Endotracheal intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intubation
Description: Endotracheal intubation
Study: NCT01155700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Study: NCT01200745

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsaicin patch
Description: Over an four-week period, the treatment group (n=30) uses capsaicin patch (100 mcg/3cc) at the tender point of neck for 12 hours a day; the control group (n=30) receives Hydrogel patch instead of capsaicin patch.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capsaicin patch
Description: Over an four-week period, the treatment group (n=30) uses capsaicin patch (100 mcg/3cc) at the tender point of neck for 12 hours a day; the control group (n=30) receives Hydrogel patch instead of capsaicin patch.
Study: NCT01361516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anaesthesia and Lithotripsy
Description: The efficacy of stone fragmentation during lithotripsy procedure is compared under two types of anaesthesia
Study: NCT02153762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Locoid Lipocream
Description: Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
Study: NCT00440557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa once weekly
Description: Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin alfa once every two weeks
Description: Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).
Study: NCT02153762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Locoid Lipocream
Description: Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
Study: NCT00867542

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02321384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6889678
Description: RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6889678
Description: RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6889678
Description: RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO6889678 or matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO6889678 or matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: RTV will be administered orally as a single dose on Day 1 in RTV-boosted SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in RTV-boosted MAD cohorts.
Study: NCT01273337

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALD-401
Description: 3 mL ALDHbr cells isolated from autologous bone marrow given as a one-time infusion via intracarotid infusion.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Sham bone marrow harvest and sham product infusion procedures.
Study: NCT01584544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Study: NCT02153762

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylatopic Plus
Description: Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
Study: NCT00171821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Study: NCT02763111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-085

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01584544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1650mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
Study: NCT02153762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hylatopic Plus
Description: Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
Study: NCT04067830

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive usual care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Surgery
Description: Undergo laparoscopic surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Surgery
Description: Undergo laparoscopic surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Muscle Training Device
Description: Use power lung device to complete RMT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-Assisted Thoracic Surgery
Description: Undergo video-assisted thoracic surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-Assisted Thoracic Surgery
Description: Undergo video-assisted thoracic surgery
Study: NCT01539980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sericin scaffold
Description: Device: wound dressing containing silk sericin A scaffold from silk sericin-polyvinyl alcohol-glycerin blending are applied on one half of the skin graft donor site Device: fine mesh gauze impregnated with paraffin and 0.5%chlorhexidine acetate (Bactigras, Smith\&Nephew, London, UK) are applied on the other half of the skin graft donor site
Study: NCT02847598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB059 (litifilimab)
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT00130286

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rosiglitazone
Description: 4 mg tablet twice a day x 12 weeks (double-blind phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: 4 mg tablet twice a day x 12 weeks (double-blind phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: 4 mg tablet twice a day x 12 weeks (double-blind phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Description: 4 mg tablet twice a day x 12 weeks (double-blind phase)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant human growth hormone + rosiglitazone
Description: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone + rosiglitazone
Description: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone + rosiglitazone
Description: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone + rosiglitazone
Description: Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)